Tvardi Therapeutics, Inc.
TVRD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7 | $46 | $46 | $7 |
| - Cash | $38 | $23 | $21 | $13 |
| + Debt | $44 | $0 | $2 | $4 |
| Enterprise Value | $14 | $23 | $27 | -$3 |
| Revenue | $7 | $21 | $42 | $23 |
| % Growth | -66% | -49.9% | 81.8% | – |
| Gross Profit | $6 | $15 | $34 | $21 |
| % Margin | 88.6% | 69.3% | 82.1% | 93.3% |
| EBITDA | -$63 | -$118 | -$84 | -$87 |
| % Margin | -877.1% | -561.1% | -200.2% | -377.3% |
| Net Income | -$71 | -$119 | -$85 | -$88 |
| % Margin | -993% | -565.2% | -204.2% | -384.1% |
| EPS Diluted | -46.59 | -1.85 | -2.2 | -62.77 |
| % Growth | -2,418.4% | 15.9% | 96.5% | – |
| Operating Cash Flow | -$61 | -$21 | -$18 | -$60 |
| Capital Expenditures | -$1 | -$2 | -$0 | -$0 |
| Free Cash Flow | -$62 | -$21 | -$18 | -$60 |